AUS
NZ
UK
CA
USA
IND
Highlights
- Cardiol Therapeutics announces expansion of MAVERIC clinical program with MAVERIC-2 trial.
- The trial will investigate CardiolRx in patients with recurrent pericarditis who discontinued IL-1 blocker therapy.
- The study aims to support an accelerated regulatory approval process and further clinical development.
Cardiol Therapeutics (TSX:CRDL), operating in the Healthcare sector, has announced the expansion of its MAVERIC clinical development program. The company plans to initiate MAVERIC-2, a late-stage clinical trial designed to evaluate its lead drug candidate, CardiolRx, specifically in patients suffering from recurrent pericarditis. This move reflects Cardiol’s focus on developing novel anti-inflammatory therapies aimed at cardiovascular diseases.
Focus on Recurrent Pericarditis
The upcoming MAVERIC-2 trial, set to begin in late 2024, will be conducted across several major pericardial disease centers in the United States and Europe. This trial will concentrate on patients who have previously discontinued interleukin-1 (IL-1) blocker therapy, which is commonly administered as a third-line treatment for managing recurrent pericarditis.
The trial aims to evaluate CardiolRx as a potential alternative to IL-1 blockers. CardiolRx, an oral drug candidate, offers a different approach to treating pericarditis, addressing the need for non-immunosuppressive options in the treatment landscape. The study is designed as a randomized, double-blind, placebo-controlled Phase II/III trial, following a structure intended to provide comprehensive and reliable data.
Goals and Structure of the MAVERIC-2 Trial
MAVERIC-2 will enroll approximately 110 participants to assess the effectiveness of CardiolRx in preventing new episodes of pericarditis after discontinuing IL-1 blocker therapy. The primary objective is to determine the drug's impact on preventing recurrence, providing a critical assessment of its efficacy in long-term management.
Secondary evaluations will include various endpoints, such as the time taken for pericarditis to recur, patient-reported chest pain severity, and levels of C-reactive protein (CRP), an inflammatory marker linked to pericarditis flare-ups. These measures aim to present a holistic view of CardiolRx’s therapeutic impact on both physical symptoms and underlying inflammatory responses.
Strategic Collaboration and Future Plans
The MAVERIC-2 trial has been developed in collaboration with an international advisory panel comprising experts in the field of pericardial diseases. This partnership seeks to refine the study design to ensure it meets high scientific standards and aligns with Cardiol Therapeutics’ long-term strategic goals.
The data collected through MAVERIC-2 will also complement the planned Phase III MAVERIC-3 trial, which is intended as a pivotal study for CardiolRx. The findings from these trials are expected to guide the regulatory path for the drug, supporting accelerated approval processes as the company seeks to bring a new option to patients with recurrent pericarditis.
CardiolRx as an Alternative to Traditional Therapies
In a statement, Cardiol Therapeutics highlighted the significance of CardiolRx as a non-immunosuppressive option compared to IL-1 blockers, which have been associated with risks from long-term use. The company emphasized the drug's mechanism, which focuses on inhibiting the assembly and activation of the NLRP3 inflammasome—a key factor in the inflammatory process that leads to pericarditis.
Previous trials, such as the MAVERIC-Pilot study, have demonstrated the potential of CardiolRx in reducing symptoms and normalizing inflammatory markers in patients. Cardiol Therapeutics aims to build on these findings as it progresses through the clinical development of its lead candidate.
